Navigation Links
Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
Date:10/23/2008

SOUTH SAN FRANCISCO, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it will hold a conference call to discuss the Company's third quarter results and provide a corporate update, including an update on the ongoing development activities for picoplatin, the Company's lead product candidate.

Jerry McMahon, Ph.D., chairman and chief executive officer, Ronald A. Martell, president and chief operating officer, Caroline Loewy, chief financial officer, and Robert De Jager, M.D., FACP, chief medical officer, will host the call beginning at 5:00 p.m. Eastern time (2:00 p.m. Pacific time) on Thursday, October 30. A press release for the third quarter ended September 30, 2008, will be released after markets close on October 30.

To participate in the live call by telephone, please dial 877-419-6593 from the U.S. or 1-719-325-4885 for international callers. In addition, the live conference call is being webcast and can be accessed on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com. A replay of the webcast will be available on the Company's website for 10 days.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... -- A new therapy developed by researchers at ... of Medicine and Columbia University Medical Center (CUMC) ... cardiovascular disease treatment. , The researchers demonstrated ... therapy could selectively inhibit blood vessel re-narrowing and ... using a balloon catheter to open narrowed or ...
(Date:8/18/2014)... with unprecedented efficiency and data storage may ... built-in electric polarizations to read and write ... popular data-driven technology. But ferroelectrics must first ... a curious habit of "forgetting" stored data. ... Department of Energy,s Brookhaven National Laboratory have ...
(Date:8/18/2014)... Fla. , Aug. 18, 2014 TNI ... biotechnology company pioneering the manufacturing and marketing of innovative ... that the Company is providing a second notice of ... In making the announcement, Noreen Griffin , ... you in advance for your participation in the Annual ...
(Date:8/16/2014)... (PRWEB) August 16, 2014 Firms ... industry provide guidance and advisory services to businesses, ... technical issues. Industry services are highly diverse as ... industry services range from geological and geophysical consulting ... “Consequently, over the past five years, the recovery ...
Breaking Biology Technology:Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Promising ferroelectric materials suffer from unexpected electric polarizations 2Promising ferroelectric materials suffer from unexpected electric polarizations 3Promising ferroelectric materials suffer from unexpected electric polarizations 4TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 2TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 3TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 4Scientific and Economic Consulting in Canada Industry Market Research Report Now Available from IBISWorld 2Scientific and Economic Consulting in Canada Industry Market Research Report Now Available from IBISWorld 3
... CHICAGO and HOBOKEN, N.J. , Aug. 2 ... Octapharma 25th Anniversary Grants Program is the Rush Hemophilia & ... program supports clinical or pre-clinical research focused on human protein therapies in hematology, ... , , ...
... 2 Tengion Inc. (Nasdaq: TNGN ) ... the position of Chief Financial Officer.  Mr. Davis comes to Tengion after ... to develop improved protein therapeutics. At its peak, Neose employed 200 individuals, ... , , ...
... LAUSANNE , Switzerland , August 2, 2010 ... its Global Films,business to Bilcare AG, one of the world,s leading providers ... . The agreement brings together complimentary capabilities and,synergy,s of two leading global ... ...
Cached Biology Technology:Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 2Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 3Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 4Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 5Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 6Tengion Appoints A. Brian Davis Chief Financial Officer 2Bilcare AG to Acquire INEOS' Global Films Business for EUR100 Million 2Bilcare AG to Acquire INEOS' Global Films Business for EUR100 Million 3
(Date:8/19/2014)... made to decrease China,s increasing caesarean section rate, suggests ... BJOG: An International Journal of Obstetrics and Gynaecology (BJOG) ... delivery rates in the world. Of 16 million babies ... the exact rate is not known, the current Chinese ... caesarean rates ranging from 36% to 58%. However, before ...
(Date:8/19/2014)... HOUSTON, Aug. 19, 2014 To improve students, ... poor grades, the University of Houston (UH) implemented ... for students at risk for failure. , ... Coordinating Board (THECB), the Department of Biology and ... first-year students taking "General Biology" for non-majors and ...
(Date:8/19/2014)... supermarkets to encourage healthier spending habits? A new study ... question by tracking the purchasing records in a supermarket ... the nutritional value of foods for sale. , The ... PhD, and Brian Wansink PhD, author of Slim by ... Hannaford Supermarkets in the Northeastern United States between January ...
Breaking Biology News(10 mins):Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3
... the Younger Dryas interval, which saw a rapid return ... it has been assumed that cooling temperatures and their ... groups. David Meltzer from the Southern Methodist University ... of Arizona in Tucson, USA, suggest otherwise in their ...
... MADISON, WI, April 12, 2010-What do obesity trends ... in Kenya, or alternative soil conservation strategies in Peru ... food and agriculture issues, and represent the world,s interdependence ... to build experiences of a broad and diverse world, ...
... Researchers at the Walter and Eliza Hall Institute have ... the female hormones oestrogen and progesterone, a finding that ... and treatments for breast cancer. The discovery, by ... Bioinformatics divisions, also explains decades of evidence linking breast ...
Cached Biology News:Bringing the world of agriculture to the classroom 2Hormone sensitivity of breast stem cells presents drug target 2
... Immunogen: synthetic peptide corresponding to the third ... dopamine receptor, conjugated to KLH. The immunizing ... and mouse gene. Physical form: Solution ... 0.01% sodium azide. Titertest method: IHC ...
Canine Chondrocytes (CnC) (500,000 cells)...
... Fluorescein 6-Fam, Hex, Tet Cy3, ... Fluorescein Tamra Black Hole Quenchers Molecular ... Tet Tamra, Joe 3 Dabcyl ... New York Double labelled probes are purified ...
... Varioskan is a high performance spectral ... and incubator. With the advanced SkanIt ... reliability for drug discovery assay development. ... fluorescence intensity, time-resolved fluorescence and photometric ...
Biology Products: